Artal Group’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Artal Group’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500,000	Closed	-$13.8M	–	160
2021 Q2	$13.8M	Sell	500,000 -500,000	-50%	-$9.83M	0.28%	74
2021 Q1	$16.5M	Sell	1,000,000 -200,000	-17%	-$4.56M	0.29%	75
2020 Q4	$22.1M	Sell	1,200,000 -200,000	-14%	-$3.58M	0.47%	54
2020 Q3	$19.1M	Sell	1,400,000 -200,000	-13%	-$3.08M	0.46%	46
2020 Q2	$28.7M	Buy	1,600,000 +1,000,000	+167%	+$15.1M	0.8%	34
2020 Q1	$5.98M	Sell	600,000 -50,000	-8%	-$410K	0.25%	69
2019 Q4	$5.29M	Sell	650,000 -100,000	-13%	-$923K	0.2%	71
2019 Q3	$7.43M	Hold	750,000	–	–	0.3%	60
2019 Q2	$9.47M	Buy	750,000 +150,000	+25%	+$1.58M	0.38%	54
2019 Q1	$6.11M	Hold	600,000	–	–	0.25%	69
2018 Q4	$4.5M	Hold	600,000	–	–	0.17%	71
2018 Q3	$6M	Buy	600,000 +100,000	+20%	+$1.16M	0.16%	70
2018 Q2	$6.33M	Buy	+500,000	New	+$6.04M	0.13%	62

Artal Group's TBIO Position: Q3 2021 in Review

Artal Group sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 500,000 shares — an estimated $13.8M sold.

Artal Group first reported a position in TBIO in Q2 2018 and held it in 13 quarters. The position peaked at $28.7M in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Artal Group reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Artal Group sold 500,000 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $13.8M.
Artal Group first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 13 quarters.
Artal Group's Translate Bio, Inc. Common Stock position peaked at $28.7M in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.